Search

EU pilot on drug repurposing

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.

Read more

Can Eltrombopag help children with ITP say goodbye to bleeding?

 

Immune thrombocytopenia (ITP) is a rare disease in children, affecting 5 in 100,000. Most children get better quickly without intervention but up to 30% will still have disease at 12 months.

Read more

EHA supports the European Medicines Agency's investigation into risk based quality management of clinical trials

EHA has responded to the EMA’s call for comments on the reflection paper on February 15.

Read more

Target audience

You are a hematologist working at an academic center or a large community hospital that is known for running clinical trials.

Read more

Terms & Conditions

EHA offers visitors a wide variety of information and a range of online services via its website.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

EBAH CME policy

Welcome to the EBAH CME Accreditation policy for EHA2024 Hybrid Congress. Below you will find an overview of the EBAH CME credits that can be collected for physical attendance as well as virtual attendance of the sessions.

Read more